Cargando…

Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2

Insulin-like Growth Factor-2 (IGF2) is important for the regulation of human embryonic growth and development, and for adults’ physiology. Incorrect processing of the IGF2 precursor, pro-IGF2(156), leads to the formation of two IGF2 proforms, big-IGF2(87) and big-IGF2(104). Unprocessed and mainly no...

Descripción completa

Detalles Bibliográficos
Autores principales: Potalitsyn, Pavlo, Mrázková, Lucie, Selicharová, Irena, Tencerová, Michaela, Ferenčáková, Michaela, Chrudinová, Martina, Turnovská, Tereza, Brzozowski, Andrzej Marek, Marek, Aleš, Kaminský, Jakub, Jiráček, Jiří, Žáková, Lenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439913/
https://www.ncbi.nlm.nih.gov/pubmed/37598269
http://dx.doi.org/10.1038/s42003-023-05239-6
_version_ 1785093056448430080
author Potalitsyn, Pavlo
Mrázková, Lucie
Selicharová, Irena
Tencerová, Michaela
Ferenčáková, Michaela
Chrudinová, Martina
Turnovská, Tereza
Brzozowski, Andrzej Marek
Marek, Aleš
Kaminský, Jakub
Jiráček, Jiří
Žáková, Lenka
author_facet Potalitsyn, Pavlo
Mrázková, Lucie
Selicharová, Irena
Tencerová, Michaela
Ferenčáková, Michaela
Chrudinová, Martina
Turnovská, Tereza
Brzozowski, Andrzej Marek
Marek, Aleš
Kaminský, Jakub
Jiráček, Jiří
Žáková, Lenka
author_sort Potalitsyn, Pavlo
collection PubMed
description Insulin-like Growth Factor-2 (IGF2) is important for the regulation of human embryonic growth and development, and for adults’ physiology. Incorrect processing of the IGF2 precursor, pro-IGF2(156), leads to the formation of two IGF2 proforms, big-IGF2(87) and big-IGF2(104). Unprocessed and mainly non-glycosylated IGF2 proforms are found at abnormally high levels in certain diseases, but their mode of action is still unclear. Here, we found that pro-IGF2(156) has the lowest ability to form its inactivating complexes with IGF-Binding Proteins and has higher proliferative properties in cells than IGF2 and other IGF prohormones. We also showed that big-IGF2(104) has a seven-fold higher binding affinity for the IGF2 receptor than IGF2, and that pro-IGF2(87) binds and activates specific receptors and stimulates cell growth similarly to the mature IGF2. The properties of these pro-IGF2 forms, especially of pro-IGF2(156) and big-IGF2(104), indicate them as hormones that may be associated with human diseases related to the accumulation of IGF-2 proforms in the circulation.
format Online
Article
Text
id pubmed-10439913
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104399132023-08-21 Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2 Potalitsyn, Pavlo Mrázková, Lucie Selicharová, Irena Tencerová, Michaela Ferenčáková, Michaela Chrudinová, Martina Turnovská, Tereza Brzozowski, Andrzej Marek Marek, Aleš Kaminský, Jakub Jiráček, Jiří Žáková, Lenka Commun Biol Article Insulin-like Growth Factor-2 (IGF2) is important for the regulation of human embryonic growth and development, and for adults’ physiology. Incorrect processing of the IGF2 precursor, pro-IGF2(156), leads to the formation of two IGF2 proforms, big-IGF2(87) and big-IGF2(104). Unprocessed and mainly non-glycosylated IGF2 proforms are found at abnormally high levels in certain diseases, but their mode of action is still unclear. Here, we found that pro-IGF2(156) has the lowest ability to form its inactivating complexes with IGF-Binding Proteins and has higher proliferative properties in cells than IGF2 and other IGF prohormones. We also showed that big-IGF2(104) has a seven-fold higher binding affinity for the IGF2 receptor than IGF2, and that pro-IGF2(87) binds and activates specific receptors and stimulates cell growth similarly to the mature IGF2. The properties of these pro-IGF2 forms, especially of pro-IGF2(156) and big-IGF2(104), indicate them as hormones that may be associated with human diseases related to the accumulation of IGF-2 proforms in the circulation. Nature Publishing Group UK 2023-08-19 /pmc/articles/PMC10439913/ /pubmed/37598269 http://dx.doi.org/10.1038/s42003-023-05239-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Potalitsyn, Pavlo
Mrázková, Lucie
Selicharová, Irena
Tencerová, Michaela
Ferenčáková, Michaela
Chrudinová, Martina
Turnovská, Tereza
Brzozowski, Andrzej Marek
Marek, Aleš
Kaminský, Jakub
Jiráček, Jiří
Žáková, Lenka
Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title_full Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title_fullStr Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title_full_unstemmed Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title_short Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2
title_sort non-glycosylated igf2 prohormones are more mitogenic than native igf2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439913/
https://www.ncbi.nlm.nih.gov/pubmed/37598269
http://dx.doi.org/10.1038/s42003-023-05239-6
work_keys_str_mv AT potalitsynpavlo nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT mrazkovalucie nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT selicharovairena nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT tencerovamichaela nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT ferencakovamichaela nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT chrudinovamartina nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT turnovskatereza nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT brzozowskiandrzejmarek nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT marekales nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT kaminskyjakub nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT jiracekjiri nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2
AT zakovalenka nonglycosylatedigf2prohormonesaremoremitogenicthannativeigf2